MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab
– Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp’s trust account and a private investment in public entity (PIPE) financing – Leading institutional […]